Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma

Launched by INSTITUT JEAN-GODINOT · Nov 28, 2022

Keywords

ClinConnect Summary

The detection and management of melanomas must be very early because the prognosis largely depends on the extent of the disease at the time of diagnosis.

For patients with melanoma, immunotherapy or dual therapy is used as treatment in unresectable and metastatic (AJCC stage IV) cases, depending on mutation status. Primary immunotherapy is possible in mutated patients in the absence of threatening progression.

However, not all patients respond well to immunotherapy, so biomarkers that predict treatment response are needed to optimize patient benefit.

The onset, development, and course of...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • metastatic melanoma
• • Whatever the mutation BRAF status
• • treated by immunotherapy or specific therapy
• • aged more than 18
• • agreeing to participate to the study
• Exclusion Criteria:
• • Patient whose treatment by immunotherapy has already started
• • Patient who have had a radiotherapy or chemotherapy treatment
• • Patient with an unknown primary melanoma, choroidal melanoma
• • Patient with other cancer (except basal cell and squamous cell skin cancer)
• • Patient with genetic predisposition for melanoma
• • aged less than 18
• • Adult not agreeing to participate to the study